<p>Egetis Therapeutics AB (publ) has released a corporate presentation detailing recent developments in its orphan drug business. The presentation highlights the launch of Emcitate® (tiratricol), the first and only approved treatment for MCT8 deficiency, in Germany following its approval in the European Union. Emcitate has been supplied to over 230 patients in more than 25 countries, including the US and EU. The company has initiated a rolling New Drug Application (NDA) with the US FDA, aiming for a complete submission in early 2026, and anticipates a US launch of Emcitate later that year. Emcitate has received Breakthrough Therapy Designation, Orphan Drug Designation, and other regulatory incentives such as market exclusivity and a potential Priority Review Voucher. Egetis is commercializing Emcitate in the EU and US through its own organization and partnering in other regions. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Egetis Therapeutics AB (publ) published the original content used to generate this news brief on January 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

ENTO

ARKG

ATRA

Reuters

Entero Therapeutics

Ark Genomic Revolution ETF

Atara Biotherap

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

ESC NEUBASE THERAPEUTI

iShares US Pharma

Health Care Select Sector SPDR

VG Health

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Egetis Therapeutics Unveils Emcitate Commercial Strategy and MCT8 Deficiency Market Expansion Plans